Skip to content


  • Add this article to your LinkedIn page
  • Add this article to your Twitter feed
  • Add this article to your Facebook page
  • Email this article
  • View or print a PDF of this page
  • Share further
  • Add this article to your Pinterest board
  • Add this article to your Google page
  • Share this article on Reddit
  • Share this article on StumbleUpon
  • Bookmark this page

Payment by result

Bob Damms

The Times

22 April 2010

The future lies not in blockbuster drugs but in niche products

Sir, Your recent briefing goes right to the heart of the emerging crisis in healthcare — the cost of innovation (“Medical blockbusters: Urgent need for more breakthrough drugs to emerge”, Business, April 16). We believe that the future lies not in blockbuster drugs but in niche products.

Pharmaceutical companies will seek to maintain profitability by developing therapies targeted at specific patient sub-populations. However, the need to recoup research and development costs means these drugs are much more expensive. Each course of Avastin may cost £25,000 or more, but targets far fewer patients.

On patent expiration the price of a drug may fall by up to 90 per cent, making it uneconomic for the originator to maintain production. So it becomes increasingly difficult to justify innovation.

Future healthcare will be determined therefore by the premium society is prepared to pay for genuinely innovative treatments. This could mean the NHS providing treatments that are generic, with access to additional treatments delivered by a payment-by- results system, where a pharmaceutical company gets paid when the treatment is effective in the individual patient.

Bob Damms
PA Consulting Group

To read the full article in The Times, click here

To visit our Technology and Innovation page, please click here.

By using this website, you accept the use of cookies. For more information on how to manage cookies, please read our privacy policy.